Home Newsfeeds Cantor Fitzgerald Downgrades Anavex Life Sciences to Neutral, Lowers Price Target to $11

Cantor Fitzgerald Downgrades Anavex Life Sciences to Neutral, Lowers Price Target to $11

Cantor Fitzgerald analyst Charles Duncan downgrades Anavex Life Sciences (NASDAQ:AVXL) from Overweight to Neutral and lowers the price target from $16 to $11.

byBenzinga Newsdesk

December 6, 2022

1 minute read

Cantor Fitzgerald analyst Charles Duncan downgrades Anavex Life Sciences (NASDAQ:AVXL) from Overweight to Neutral and lowers the price target from $16 to $11.

Asia
News

Chinese EV Trio Reports September Deliveries: Nio Holds Up, XPeng Slips And Li Auto Sizzles After Anemic August

By Shanthi Rexaline

October 1, 1:10 PM

Nio, Inc. (NYSE: NIO), XPeng, Inc. (NYSE: XPEV) and Li Auto, Inc.

Analyst Ratings

Analyst Expectations for Lennox Intl’s Future

By Benzinga Insights

November 29, 9:00 AM

Analysts have provided the following ratings for Lennox Intl (NYSE:LII) within the last quarter: Bullish Somewhat Bullish Indifferent…

LII

Inhibikase Therapeutics Announces Dosing Of First Patient In Its Phase 2a ‘201’ Clinical Trial Of IkT-148009 To Treat Parkinson’s Disease

By Benzinga Newsdesk

August 23, 8:04 AM

nhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced dosing of the

IKT

Recap of Tuesday’s Biotech Catalysts – End Of The Day Summary

By Ragothaman Srinivasan

July 19, 6:11 PM

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

ALNA

Cantor Fitzgerald Downgrades Anavex Life Sciences to Neutral, Lowers Price Target to $11

Related Posts

Chinese EV Trio Reports September Deliveries: Nio Holds Up, XPeng Slips And Li Auto Sizzles After Anemic August

Analyst Expectations for Lennox Intl’s Future

Inhibikase Therapeutics Announces Dosing Of First Patient In Its Phase 2a ‘201’ Clinical Trial Of IkT-148009 To Treat Parkinson’s Disease

Recap of Tuesday’s Biotech Catalysts – End Of The Day Summary